论文部分内容阅读
采用酶联免疫法测定肿瘤病人血浆IL－2、SIL－2R、IL－8含量的变化，探讨其与肿瘤的发生机制，观察疗效及估计预后。良性垂体瘤组IL－2、SIL－2R、IL-8与正常对照组相比未见明显改变（P＞0．05）。胶质瘤、胃癌、肺癌组病例IL－2、SIL－2R含量有明显改变（P＜0．05）。肺癌组病例IL－8含量明显增高（P＜0．05）。胃癌组手术前IL－2、SIL－2R与癌肿全切后IL－2、SIL－2R比较，有显著改变（P＜0．01）。晚期癌症组IL－2、SIL－2R、IL－8与癌肿全切病例比较均有明显改变（P＜0．05）。研究提示，癌肿病例IL－2、SIL－2R含量表达异常可能为癌肿的发病原因之一，而晚期癌肿病例IL－8含量的显著增高可能与其病程有关。
The plasma levels of IL-2, SIL-2R, and IL-8 in patients with tumors were measured by enzyme-linked immunosorbent assay, and the mechanism of the occurrence of tumors was investigated. The efficacy and prognosis were also evaluated. There were no significant changes in IL-2, SIL-2R and IL-8 levels in benign pituitary tumors compared with normal controls (P>0.05). The levels of IL-2 and SIL-2R in glioma, gastric cancer, and lung cancer groups were significantly changed (P<0.05). The content of IL-8 in the lung cancer group was significantly higher (P<0.05). In the gastric cancer group, IL-2 and SIL-2R were significantly changed after surgical excision of IL-2 and SIL-2R (P<0.01). In the advanced cancer group, IL-2, SIL-2R, and IL-8 all showed significant changes compared with the cases with cancer (P<0.05). Studies have shown that the abnormal expression of IL-2 and SIL-2R in cancer cases may be one of the causes of cancer. The significant increase of IL-8 levels in advanced cancer cases may be related to the course of the disease.